# Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions

> **NCT04411940** · PHASE1 · COMPLETED · sponsor: **Cycle Pharmaceuticals Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Haloperidol Tablets, Mylan Pharmaceuticals Inc.
- **DRUG:** Haloperidol Tablets, Cycle Pharmaceuticals Ltd

## Key facts

- **NCT ID:** NCT04411940
- **Lead sponsor:** Cycle Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2019-12-18
- **Final completion:** 2019-12-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04411940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04411940, "Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04411940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*